The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22)

Neumann, Frank; Poelitz, Anne; Hildebrandt, Barbara; Fenk, Roland; Haas, Rainer; Royer‐Pokora, Brigitte; Germing, Ulrich

doi:10.1038/sj.leu.2404557

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the medical literature, we were only able to find 11 cases of t(4;22)(q12;q11.2) reported worldwide, with varying treatments and outcomes (Table 1). Myeloid neoplasms account for nine of the 11 reported cases, along with 1 case of B myeloid-mixed leukemia and one case of T-cell acute lymphoblastic leukemia [6][7][8][9]. To the best of our knowledge, this is the first reported case of B-ALL with BCR::PDGFRA fusion.…”

Section: Discussionmentioning

confidence: 99%

BCR::ABL1-Like B-Cell Acute Lymphoblastic Leukemia with BCR::PDGFRA Fusion: A Case Report and Literature Review

Hua,

Yan,

Qian

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

Introduction: We report a case of B-cell acute lymphoblastic leukemia (B-ALL) involving the breakpoint cluster region (BCR) and platelet-derived growth factor receptor alpha (PDGFRA) (BCR::PDGFRA) fusion gene, classified as a BCR::ABL1-like subtype. To our knowledge, this is the first such report. Case Presentation: The patient tested negative for BCR::ABL1 fusion. t(4;22)(q12;q11.2) was detected by karyotype analysis. BCR::PDGFRA transcripts were detected by RNA sequencing. Dasatinib combined with chemotherapy was ineffective. Furthermore, an EZH2 mutation was detected. Imatinib, which led to complete remission, was administered; flow cytometry revealed that the minimal residual disease had dropped to 0.008% and RT-qPCR revealed that BCR::PDGFRA/ABL1 dropped to 9.18x104. Conclusion: It is noteworthy that imatinib was more effective than dasatinib in our case, although the duration of remission was short. Our findings suggest that other therapies like allogeneic hematopoietic stem cell transplantation may need to be combined to improve long-term survival in ALL cases with BCR::PDGFRA.

show abstract

Section: Discussionmentioning

confidence: 99%

BCR::ABL1-Like B-Cell Acute Lymphoblastic Leukemia with BCR::PDGFRA Fusion: A Case Report and Literature Review

Hua,

Yan,

Qian

et al. 2023

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Imatinib is a potent inhibitor of the receptor tyrosine kinases Bcr-Abl (in human chronic myelogenous leukemia), PDGFRα and PDGFRβ, and c-kit. 53 We used imatinib to probe the functional role of PDGFRβ activation in the pro-fibrotic phenotype of cMSCs and cardiac remodeling in HF. In vivo administration of imatinib to mice with established cardiac remodeling and HF abrogated progression of LV dysfunction and improved remodeling at both the chamber and tissue level, including salutary effects on border zone fibrosis, capillary density, and CCR2 + monocyte-derived macrophage infiltration.…”

Section: Discussionmentioning

confidence: 99%